Nymox Pharmaceutical director Robinson buys in the market again

Posted on by

Nymox Pharmaceutical Corp. {NASDAQ: NYMX} Director James George Robinson purchased 22,500 shares of the company’s stock in a transaction dated Friday, July 29th.

The stock was purchased at an average price of $3.86 per share, for a total transaction of $86,850.00.

 

 

Nymox Pharmaceutical Corp. {NASDAQ: NYMX} Director James George Robinson purchased 22,500 shares of the company’s stock in a transaction dated Friday, July 29th.

 

The stock was purchased at an average price of $3.86 per share, for a total transaction of $86,850.00.

 

Following the completion of the purchase, the director now owns 2,880,050 shares in the company, valued at $11,116,993.

 
Nymox Pharmaceutical Corp., formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.